Tehran Heart Center, Tehran University of Medical Sciences, Iran.
Arch Iran Med. 2012 Jan;15(1):32-5.
The implantation of a CD133+ bone marrow cell population into an ischemic myocardium has emerged as a promising therapeutic modality for myocardial regeneration and restoration of ventricular contractility. While previous studies have documented the short-term safety and efficacy of CD133+ cell transplantation in patients with acute myocardial infarction, there are few reports of long-term follow-up results. Here, we present the results of long-term follow-up of our acute myocardial infarction patients who were treated with intramyocardial injection of CD133+ cells after coronary bypass graft.
After five years, 13 patients in the cell transplantation group and 5 patients in the control group underwent safety and efficacy investigations by New York Heart Association classification and two-dimensional echocardiography (2D echo).
During the five-year study period, no major cardiac adverse events were reported among patients who received CD133+ stem cells. Regarding efficiency, we observed no statistically significant treatment effects for the echocardiographic parameters [left ventricular end-diastolic and end-systolic volumes, and resting ejection fraction] measured during the follow-up period. However, detailed analysis of regional wall motion revealed an improvement in the Wall Motion Score Index from baseline to the six month follow-up, which was maintained during the follow-up period.
Taken together, the long-term results of the present study indicate that transplantation of CD133+ is a safe and feasible procedure; however, we could not show any major benefits in our patients. Thus, this issue needs to be addressed by conducting other studies with more patients.
将 CD133+骨髓细胞群植入缺血性心肌已成为心肌再生和恢复心室收缩力的一种很有前途的治疗方法。虽然以前的研究已经证明了 CD133+细胞移植在急性心肌梗死患者中的短期安全性和有效性，但很少有关于长期随访结果的报道。在这里，我们报告了在冠状动脉旁路移植术后通过心肌内注射 CD133+细胞治疗急性心肌梗死患者的长期随访结果。
五年后，细胞移植组的 13 名患者和对照组的 5 名患者接受了纽约心脏协会分类和二维超声心动图（2D 回声）的安全性和疗效调查。
在五年的研究期间，接受 CD133+干细胞治疗的患者没有发生重大心脏不良事件。关于效率，我们没有观察到随访期间超声心动图参数（左心室舒张末期和收缩末期容积和静息射血分数）有统计学意义的治疗效果。然而，对局部壁运动的详细分析显示，从基线到 6 个月随访时的壁运动评分指数有所改善，并且在随访期间得到了维持。
综上所述，本研究的长期结果表明，CD133+的移植是一种安全可行的方法；然而，我们的患者并没有显示出任何明显的益处。因此，这个问题需要通过更多患者的其他研究来解决。
